Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.
OBJECTIVE
It was reported that exenatide ameliorated renal injury in diabetic rats. The present study was carried out to evaluate the effect of exenatide on 24-hour urinary albumin, urinary transforming growth factor-β(1) (TGF-β(1)) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.


METHODS
31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks. Body mass index (BMI), fasting plasma glucose, 2-hour postprandial plasma glucose, glycated hemoglobin A(1c), systolic blood pressure, diastolic blood pressure, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen concentration were analyzed between the two treatment groups. 20 age- and BMI-matched healthy subjects were chosen as the normal control group (group NC, n = 20).


RESULTS
After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups.


CONCLUSIONS
Our results indicate that exenatide reduces urinary TGF-β(1) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria, which may be partly contributory to its directly renoprotective role.
Department of Endocrinology, Huaian First Hospital Affiliated to Nanjing Medical University, Huaian, PR China.
Hong
H
Zhang
Xiangcheng
X
Zhang
Changjun
C
Hu
Weiping
W
Lu
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000188:drug therapy / Q000453:epidemiology / Q000652:urine*; D015415:Biomarkers / Q000652:urine; D024141:Collagen Type IV / Q000037:antagonists & inhibitors / Q000652:urine*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology / Q000652:urine*; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors / Q000652:urine*; D014688:Venoms / Q000627:therapeutic use*
D015415:Biomarkers; D024141:Collagen Type IV; D007004:Hypoglycemic Agents; D010455:Peptides; C508960:TGFB1 protein, human; D053773:Transforming Growth Factor beta1; D014688:Venoms; D000077270:Exenatide